We advised the joint book-running managers and underwriters on the offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a public offering by IDEAYA Biosciences, Inc. of 7,222,225 shares of common stock at $27.00 per share and pre-funded warrants to purchase 5,555,576 shares of common stock at $26.9999 per pre-funded warrant, which included 1,666,669 shares of common stock from the full exercise of the underwriters’ option to purchase additional shares, for total gross proceeds of approximately $345 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “IDYA.”

Based in South San Francisco, California, IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Alexander Curtis and Yan Zhan. The tax team included counsel Dustin Plotnick and associates Fred (Chen) Fu and Serena Cheng. The intellectual property team included partner David R. Bauer and associates Anne Kim and Ryan Grawe. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post